QURE — uniQure N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1590560 ·
Netherlands
Last close
$48.16
Market Cap
$3.04B
52W High
$49.70
52W Low
$13.21
ADV30
2,378,277
Next earnings
2026-07-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 3,562,000 | 3,343,000 | -44,269,000 | -53,535,000 | 778,706,000 | 139,994,000 | 629,363,000 |
| Dec 2025 | 5,568,000 | 5,133,000 | -51,494,000 | -37,086,000 | 824,908,000 | 80,240,000 | 626,007,000 |
| Sep 2025 | 3,701,000 | 3,303,000 | -49,489,000 | -80,529,000 | 888,382,000 | 597,056,000 | 659,636,000 |
| Jun 2025 | 5,262,000 | 4,606,000 | -42,885,000 | -37,719,000 | 584,890,000 | 253,778,000 | 588,893,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-172,106,000
Investing CF
$-243,158,000
Financing CF
$335,278,000
CapEx
$-645,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.74
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,382,471,000
Inventory
$0
Receivables
$3,562,000
ST Investments
$446,556,000
EBIT TTM
$-142,330,000
Pretax Income TTM
$-203,246,000
Interest Exp TTM
$60,916,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$18,093,000
EBITDA
$-174,856,992
Free Cash Flow
$-103,697,624
Enterprise Value
$1,661,297,408
Total Cash
$586,550,016
Total Debt
$545,656,000
Shares Out
63,067,485
Trailing EPS
$-3.49
Book Value
$3.19
ROE
-228.2%
ROA
-17.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 16,098,000 | -187,827,000 | -198,971,000 | 824,908,000 | 626,007,000 | — | -177,963,000 |
| Dec 2024 | 27,119,000 | -182,180,000 | -239,556,000 | 556,536,000 | 563,288,000 | — | -182,728,000 |
| Dec 2023 | 15,843,000 | -282,486,000 | -308,478,000 | 831,689,000 | 624,019,000 | — | -145,929,000 |
| Dec 2022 | 106,483,000 | -144,246,000 | -126,789,000 | 704,964,000 | 228,955,000 | — | -145,060,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.82
Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $30.00 · spot: $48.16 · call volume: 6,132 · put volume: 1,986Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RCUS | Arcus Biosciences, Inc. | $3.03B | $24.12 | — |
| IDYA | IDEAYA Biosciences, Inc. | $2.96B | $31.26 | — |
| ELVN | Enliven Therapeutics, Inc. | $3.13B | $44.86 | — |
| DYN | Dyne Therapeutics, Inc. | $3.17B | $19.20 | — |
| GPCR | Structure Therapeutics Inc. | $3.20B | $45.00 | — |
News headlines (Yahoo Finance, 1h cache)
UniQure (QURE) Soars 78% on AMT-130 Progress
2026-06-18 00:08 · Yahoo
Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End
2026-06-17 20:15 · Yahoo
UniQure Catapults Nearly 80% On A Gene Therapy Shock From The FDA
2026-06-17 20:13 · Yahoo
Sector Update: Healthcare Stocks Retreat Late Afternoon
2026-06-17 19:38 · Yahoo
This Biotech Stock Is Surging 81% on Surprise Good News From FDA
2026-06-17 19:33 · Yahoo
Stocks Mixed Ahead of FOMC Meeting Results
2026-06-17 15:22 · Yahoo
QURE Stock Surges Over 70% After FDA Softens Stance On Huntington’s Disease Gene Therapy
2026-06-17 13:08 · Yahoo
ClearPoint Neuro Shares Jump as FDA Progress for UniQure Therapy Highlights Platform Value
2026-06-17 12:56 · Yahoo
uniQure Positioned for Gains After FDA Supports Accelerated Approval Path for AMT-130
2026-06-17 12:55 · Yahoo
uniQure Plans FDA BLA Submission for AMT-130 in Huntington's Disease in Q3
2026-06-17 11:43 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.